Noor, 2023 - Google Patents
A Short Review on 4P Domain in Oncology (Personalized, Predictive, Preventive and Participative)Noor, 2023
View PDF- Document ID
- 4973834229362634841
- Author
- Noor H
- Publication year
- Publication venue
- South Asian Res J Med Sci
External Links
Snippet
Since the 1970s, our society has been undergoing rapid digitalization. This has been paralleled by rapid advancements in biology, in particular with the sequencing of the human genome and the development of proteomics and metabolomics. This digital world presents …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kelloff et al. | Cancer biomarkers: selecting the right drug for the right patient | |
CN112289455A (en) | Artificial intelligence neural network learning model construction system and construction method | |
CN112086129B (en) | Method and system for predicting cfDNA of tumor tissue | |
CN105506115B (en) | DNA library for detecting and diagnosing genetic cardiomyopathy pathogenic genes and application thereof | |
US20100189318A1 (en) | Methods for constructing association maps of imaging data and biological data | |
JP2023541368A (en) | Method and system for cell-free DNA fragment size density for evaluating cancer | |
CN116385441B (en) | Method and system for risk stratification of oligodendroglioma based on MRI | |
Aghamaleki et al. | Application of an artificial neural network in the diagnosis of chronic lymphocytic leukemia | |
CN113462775B (en) | Gene markers for prognosis evaluation of colorectal cancer | |
CN108559777A (en) | A kind of New molecular marker and its application in preparing for the kit of clear cell carcinoma of kidney diagnosis and prognosis | |
Venkatesan et al. | Diagnostic and therapeutic approach of artificial intelligence in neuro-oncological diseases | |
Wang et al. | Comparison and screening of different risk assessment models for deep vein thrombosis in patients with solid tumors | |
CN105567846A (en) | Kit for detecting bacteria DNAs in faeces and application thereof in colorectal cancer diagnosis | |
KR101223270B1 (en) | Method for determining low―mass ions to screen colorectal cancer, method for providing information to screen colorectal cancer by using low―mass ions, and operational unit therefor | |
CN110004229A (en) | Application of the polygenes as EGFR monoclonal antibody class Drug-resistant marker | |
Noor | A Short Review on 4P Domain in Oncology (Personalized, Predictive, Preventive and Participative) | |
US20190252040A1 (en) | Detection of cancer-specific diagnostic markers in genome | |
CN106755322A (en) | A kind of kit and its application method for predicting lung cancer metastasis | |
US20190385696A1 (en) | Method for predicting disease risk based on analysis of complex genetic information | |
KR20150043790A (en) | Extracting method for biomarker for diagnosis of biliary tract cancer, computing device therefor, biomarker for diagnosis of biliary tract cancer, and biliary tract cancer diagnosis device comprising same | |
Elangovan et al. | Comparative Analysis of Machine Learning Models for Early Prediction of Cancer | |
Xu et al. | Preoperative contrast-enhanced CT-based deep learning radiomics model for distinguishing retroperitoneal lipomas and well‑differentiated liposarcomas | |
US12094107B2 (en) | CAD device and method for analyzing medical images | |
EP4417704A1 (en) | Method for creating biomarker set for detecting cancer | |
Haga | No Two Cancers the Same |